Australia · Delayed Price · Currency is AUD Healius Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 earnings improved, while Q1 FY 2027 pathology revenue and cost trends supported reaffirmed guidance. Shareholders challenged cash generation, returns and remuneration; the board expects positive cash flow in FY 2027 and recorded a first strike on the remuneration report.
-
Underlying revenue grew 2.1% to AUD 1.37 billion, with strong cost control driving margin improvement and an 8.1% rise in EBITDA. FY 2027 EBIT is guided at AUD 39.7 million, with continued focus on profitable growth, digital transformation, and cost discipline.
-
Revenue grew 3.8% to AUD 688.1 million in H1 FY26, with underlying EBITDA up 13.1% and EBIT improving to AUD 7.9 million. Cost savings, digital transformation, and high-value segment growth are driving margin expansion, with FY26 EBIT expected in line with consensus at around AUD 48 million.
Fiscal Year 2025
-
The AGM highlighted a successful year with the sale of Lumus Imaging, debt repayment, and a special dividend. Strategic focus remains on digital modernization, operational efficiency, and achieving high single-digit EBIT margins by FY 2027. Shareholders supported all resolutions, and the Board addressed concerns on cash flow, competition, and remuneration alignment.
-
Revenue grew 5.7% to AUD 1.34 billion, with pathology up 6% and genomics up 34.7%. Labor costs are targeted to remain flat in FY 2026, with AUD 15–20 million in cost savings planned. High single-digit margins are targeted by June 2027.
-
A simplified, digitally enabled business model is being implemented, targeting high single-digit EBIT margins by June 2027. Key initiatives include the sale of Lumus Imaging, aggressive cost reduction, and expansion of non-MBS revenue streams such as genomics, vet pathology, and clinical trials. Digital transformation and operational standardization underpin efficiency and growth.
-
Group revenue rose 10% year-over-year, driven by strong pathology and Lumus Imaging growth, though higher labor costs weighed on margins. The sale of Lumus Imaging for AUD 965 million will fund debt repayment and a likely special dividend, with further transformation and productivity gains targeted in 2H25.
Fiscal Year 2024
-
The meeting focused on the sale of Lumus Imaging, strategic refocus on pathology, and leadership changes. Shareholders will receive a special dividend post-sale, and the board addressed margin challenges, digital transformation, and ongoing advocacy for pathology funding. Voting outcomes and constitutional changes were also covered.
-
Group revenue grew 6.1% to AUD 1.74 billion, with EBIT at the top end of guidance and strong segment growth in pathology, imaging, and Agilex. Transformation initiatives exceeded targets, and the Lumus Imaging sale is progressing. Margin and volume improvements continue into FY 2025.